These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1179 related articles for article (PubMed ID: 17481774)
1. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Akhtar S; Benter I Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774 [TBL] [Abstract][Full Text] [Related]
2. Cationic lipids and polymers mediated vectors for delivery of siRNA. Zhang S; Zhao B; Jiang H; Wang B; Ma B J Control Release; 2007 Oct; 123(1):1-10. PubMed ID: 17716771 [TBL] [Abstract][Full Text] [Related]
3. RNA interference (RNAi) in hematology. Scherr M; Steinmann D; Eder M Ann Hematol; 2004 Jan; 83(1):1-8. PubMed ID: 14574462 [TBL] [Abstract][Full Text] [Related]
4. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Takahashi Y; Nishikawa M; Takakura Y Adv Drug Deliv Rev; 2009 Jul; 61(9):760-6. PubMed ID: 19386274 [TBL] [Abstract][Full Text] [Related]
5. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Spagnou S; Miller AD; Keller M Biochemistry; 2004 Oct; 43(42):13348-56. PubMed ID: 15491141 [TBL] [Abstract][Full Text] [Related]
6. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. Aigner A J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079 [TBL] [Abstract][Full Text] [Related]
7. RNAi in functional genomics. Scherr M; Eder M Curr Opin Mol Ther; 2004 Apr; 6(2):129-35. PubMed ID: 15195923 [TBL] [Abstract][Full Text] [Related]
8. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery. Singh SK; Hajeri PB Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929 [TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Li SD; Huang L Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838 [TBL] [Abstract][Full Text] [Related]
10. Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics. Akhtar S Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1347-62. PubMed ID: 20929276 [TBL] [Abstract][Full Text] [Related]
11. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors. Sun Y; Li Z; Li L; Li J; Liu X; Li W Int J Mol Med; 2007 Apr; 19(4):705-11. PubMed ID: 17334648 [TBL] [Abstract][Full Text] [Related]
12. Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing. Luo Q; Kang Q; Song WX; Luu HH; Luo X; An N; Luo J; Deng ZL; Jiang W; Yin H; Chen J; Sharff KA; Tang N; Bennett E; Haydon RC; He TC Gene; 2007 Jun; 395(1-2):160-9. PubMed ID: 17449199 [TBL] [Abstract][Full Text] [Related]